Commercial Assessment Of The Diabetic Nephropathy Market 2026-2036 Featuring Boehringer Ingelheim, Eli Lilly, Bayer, Astrazeneca, UCB Biopharma, Serodus, And Palatin
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The diabetic nephropathy and diabetes kidney disease (DKD) market reached approximately USD 8.80 billion in 2025 across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Supported by increasing disease prevalence, earlier intervention, broader adoption of targeted therapies, and continued pharmaceutical innovation, the market is expected to expand at a compound annual growth rate of approximately 5% from 2026 to 2036.
The report providesan in-depth assessment of historical and forecast epidemiology, treatment practices, market size, therapy uptake, pricing trends, competitive positioning, and unmet medical needs across the 7MM.
Key Diabetic Nephropathy and Diabetes Kidney Disease Market Findings
- The DKD market was valued at approximately USD 8.80 billion across the 7MM in 2025. The total prevalent DKD population in the 7MM was estimated at nearly 34 million cases in 2025 and is projected to increase during the forecast period. The United States accounted for nearly 15 million prevalent cases in 2025 and represented the largest regional market. Approximately 70% of US DKD cases occurred among individuals aged 60 years and older, compared with around 30% among those aged 18-59 years. Germany recorded the highest prevalent population among the EU4 and the United Kingdom in 2025, followed by Spain, while France had the lowest number of cases. Approximately 95% of Japanese patients with Stage 2-4 disease were estimated to actively seek treatment. Antidiabetic therapies generated the highest DKD-related revenue across the 7MM in 2025.
The concentration of DKD among older adults reflects its association with long-standing diabetes and progressive renal impairment. This trend reinforces the importance of annual renal function and albuminuria assessments, timely diagnosis, sustained glycemic and blood pressure management, and earlier use of therapies with demonstrated kidney and cardiovascular benefits.
DKD Treatment Landscape Continues to Evolve
Current diabetic kidney disease management follows an individualized, stepwise approach designed to preserve renal function, slow disease progression, and reduce cardiovascular morbidity and mortality. Treatment strategies include lifestyle management, glycemic control, blood pressure and lipid management, renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and other glucose-lowering therapies selected according to renal function and comorbidities.
SGLT2 inhibitors, including empagliflozin (JARDIANCE) and dapagliflozin (FARXIGA/FORXIGA), have contributed to a significant shift in clinical practice because of evidence supporting renal and cardiovascular protection. Finerenone (KERENDIA), a non-steroidal mineralocorticoid receptor antagonist, has further expanded the treatment landscape by targeting pathways associated with inflammation and fibrosis.
Leading companies in the marketed DKD therapeutics landscape include Boehringer Ingelheim and Eli Lilly with JARDIANCE, Bayer with KERENDIA, and AstraZeneca with FARXIGA/FORXIGA. The competitive environment also includes UCB Biopharma, Daiichi Sankyo, Serodus, Palatin Technologies, Novo Nordisk, and Inversago Pharma, among others.
In March 2026, a Phase III study of KERENDIA reported that the therapy met its primary endpoint in patients with chronic kidney disease, demonstrating a statistically significant improvement in the estimated glomerular filtration rate slope compared with placebo. The reported safety profile was consistent with previous findings.
Emerging DKD Pipeline Supports Future Market Growth
The diabetic nephropathy and diabetes kidney disease pipeline includes therapies targeting distinct metabolic, hemodynamic, inflammatory, and fibrotic pathways. Notable candidates include esaxerenone (MINNEBRO) from Daiichi Sankyo, SER150 from Serodus, bremelanotide (VYLEESI) from Palatin Technologies, and INV-202 from Novo Nordisk and Inversago Pharma.
These candidates are being evaluated across different stages of renal impairment, reflecting increased industry focus on stage-specific treatment and prevention of disease progression. Uptake of emerging therapies is expected to depend on clinical efficacy, safety, administration requirements, regulatory outcomes, reimbursement, guideline inclusion, and differentiation from established standards of care.
Recently introduced targeted therapies are anticipated to achieve moderate to high uptake as physician confidence in early cardio-renal intervention increases. Pipeline products may experience more gradual adoption while confirmatory clinical data, real-world evidence, and market access frameworks continue to develop.
Persistent Unmet Needs Create Strategic Opportunities
Despite advances in treatment, the DKD market continues to face major clinical and commercial challenges. Priority unmet needs include:
- Limited availability of therapies capable of delivering sustained disease modification across diverse patient populations Persistent cardiovascular risk and mortality despite optimized treatment Delayed diagnosis and inconsistent implementation of early screening Insufficiently sensitive and predictive biomarkers for progression and treatment response Complex medication selection and dose management in patients with impaired renal function Differences in treatment access, affordability, adherence, and reimbursement across markets
These gaps create opportunities for developers advancing differentiated therapies that can improve renal outcomes, reduce cardiovascular events, demonstrate favorable safety, and support convenient long-term disease management.
Comprehensive DKD Market Intelligence and Competitive Analysis
The report evaluates the diabetic kidney disease market from 2022 through 2036, including patient population forecasts, therapy-specific revenue, market share, drug adoption, peak patient share, pricing, analogue assessment, and geographic growth opportunities. Drug profiles review mechanisms of action, clinical trial findings, regulatory milestones, patents, collaborations, strategic partnerships, advantages, limitations, and recent developments.
The analysis also incorporates insights from key opinion leaders and subject-matter experts across the 7MM. Research engagement included specialists associated with institutions such as the University of North Carolina at Chapel Hill, the Berlin Institute of Health at Charite, and the University of Nottingham. Expert perspectives were used to assess evolving treatment practices, prescribing patterns, patient adherence, therapy switching, market access barriers, pipeline prioritization, and epidemiological trends.
Qualitative assessment includes SWOT and conjoint analyses covering efficacy, safety, route and frequency of administration, order of market entry, probability of success, cost-effectiveness, geographic accessibility, and addressable patient populations. These findings support pharmaceutical companies, investors, healthcare organizations, and other stakeholders in evaluating DKD market attractiveness and developing evidence-based clinical, commercial, and market access strategies.
Report Coverage
- Diabetic nephropathy and diabetes kidney disease epidemiology forecasts across the 7MM Historical and forecast DKD therapeutics market size from 2022 to 2036 Current treatment practices and evolving therapeutic algorithms Approved and emerging drug profiles Clinical development and competitive landscape analysis Therapy uptake, peak patient share, pricing, and market access trends Unmet medical needs and future treatment opportunities Expert insights, SWOT analysis, and conjoint analysis Market outlook for North America, Europe, and Asia-Pacific
Rising prevalence, the transition toward targeted cardio-renal therapies, and continued pipeline development are expected to sustain growth in the diabetic nephropathy and diabetes kidney disease market through 2036. Companies capable of addressing early diagnosis, renal preservation, cardiovascular risk, treatment accessibility, and long-term adherence will be well positioned to capture emerging opportunities across the 7MM.
A selection of companies mentioned in this report includes, but is not limited to:
- Boehringer Ingelheim Eli Lilly Bayer AstraZeneca UCB Biopharma Serodus Palatin
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment